Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.20.1
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2020
Dec. 31, 2019
Current assets:    
Cash $ 2,184,831 $ 2,598,864
Advances on research and development contract services 43,411
Accrued interest receivable 285 14,367
Prepaid expenses and other current assets 47,750 58,802
Total current assets 2,276,277 2,672,033
Total assets 2,276,277 2,672,033
Current liabilities:    
Accounts payable and accrued expenses 160,927 143,549
Research and development contract liabilities 64,390 94,349
Total current liabilities 225,317 237,898
Commitments and contingencies
Stockholders' equity:    
Preferred Stock, $0.0001 par value; authorized - 10,000,000 shares; issued and outstanding - 350,000 shares of Series A Convertible Preferred Stock, $10.00 per share stated value, $50.00 per share cash redemption value; aggregate cash redemption value - $17,500,000; liquidation preference based on assumed conversion into common shares - 4,375,000 shares 3,500,000 3,500,000
Common stock, $0.0001 par value; authorized - 100,000,000 shares; issued and outstanding - 67,045,814 shares 6,704 6,704
Additional paid-in capital 26,016,317 26,016,317
Accumulated deficit (27,472,061) (27,088,886)
Total stockholders' equity 2,050,960 2,434,135
Total liabilities and stockholders' equity $ 2,276,277 $ 2,672,033